SFB1399: Univ. Prof. Dr. rer. nat. Hans-Georg Rammensee

Academic education

1974 - 1980: Biology studies at the University of Tübingen
1980: Diploma thesis in the laboratory of Professor Dr. Jan Klein at the Max Planck Institute for Biology, Tübingen

Scientific degrees

1991: Habilitation (postdoctoral teaching qualification) in immunology, University of Tübingen
1980 - 1982: PhD Thesis ("Dr. rer. nat.") at the Max Planck Institute for Biology on minor histocompatibility antigens (Supervisor: Professor Dr. Jan Klein)

Scientific career

2019 - present: Co-chair of the Cluster of Excellence iFIT (EXC 2180) at the University of Tübingen
2012 - present: Deputy site coordinator of the German Consortium for Translational Cancer Research (DKTK) and overall coordinator of the DKTK research program Cancer Immunotherapy
2005 - 2017: Chairman of the SFB 685: Immunotherapy: Molecular basis and clinical application
2002 - 2012: Chairman of the Graduiertenkolleg 794: Graduate School for Cellular Mechanisms of Immune-associated Processes
2000: Co-founder of the biotechnology enterprises immatics GmbH and Curevac GmbH
1996 - present: Chair, Department of Immunology (Full Professor, C4), Institute for Cell Biology, University of Tübingen, Germany
1993 - 1996: Head of Department, Tumor-Virus-Immunology Section, German Cancer Research Center (DKFZ), Heidelberg; appointment as Professor, University of Heidelberg
1987 - 1993: Group leader at the Department of Immunogenetics, Max Planck Institute for Biology, Tübingen, Germany
1985 - 1987: Scientific Member of the Basel Institute for Immunology
1982 - 1985: Postdoctoral research fellow in the laboratory of Michael J. Bevan, PhD, at Scripps Clinic, La Jolla, CA, USA

Honors/ Awards/ Memberships

2016: Ernst Jung Prize for Medicine
2016: Wilhelm Warner Foundation
2014: German Cancer Aid Award
2014: Advanced Grant, European Research Council (ERC)
2013: The Hansen Family Award, Bayer Science and Education Foundation
1997: Rose Payne Distinguished Scientist Award 1996 Paul Ehrlich und Ludwig Darmstaedter Prize
1993: Robert Koch Prize 1992 Avery Landsteiner Prize 1992 Gottfried Wilhelm Leibniz Prize
1991: Wilhelm und Maria Meyenburg Prize
1988: Heinz-Maier-Leibnitz Prize Krebsforschungszentrum

Membership in advisory boards (selection)

2011 - present: Member of the Scientific Advisory Board, RCI Regensburg Center for Interventional Immunology
2006 - present: Co-opted member of the Scientific Council of the Paul Ehrlich Foundation; Advisory Board Member, BayImmuNet; Member of the Academy of Sciences and Literature, Mainz
2002 - present: Member of the Academy of Cancer Immunology
2002 - present: Co-founder and board member of the Association for Cancer Immunotherapy (CIMT)
1998 - 2018: Board member of the Cooperation Program in Cancer Research (German Cancer Research Center Heidelberg and the Ministry of Science, Israel)

10 most relevant publications

Dimitrov S, Gouttefangeas C, Besedovsky L, Jensen ATR, Chandran PA, Rusch E, Businger R, Schindler M, Lange T, Born J, Rammensee HG. Activated integrins identify functional antigen-specific CD8(+) T cells within minutes after antigen stimulation. Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5536-E5545.
Loffler MW, Kowalewski DJ, Backert L, Bernhardt J, Adam P, Schuster H, Dengler F, Backes D, Kopp HG, Beckert S, Wagner S, Konigsrainer I, Kohlbacher O, Kanz L, Konigsrainer A, Rammensee HG, Stevanovic S, and Haen SP. Mapping the HLA ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation Cancer Res. 2018 Aug 15;78(16):4627-4641.
Schuster H, Peper JK, Bosmuller HC, Rohle K, Backert L, Bilich T, Ney B, Loffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee HG, Stevanovic S, Staebler A, and Wagner P. The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951.
Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75.
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014 Nov 27;515(7528):577-81.
Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, and Singh-Jasuja H. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012 Aug; 18(8):1254-61.
Drexler I, Staib C, Kastenmuller W, Stevanovic S, Schmidt B, Lemonnier FA, Rammensee HG, Busch DH, Bernhard H, Erfle V, and Sutter G. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci USA 2003 Jan; 100(1): 217-22.
Rammensee HG, Bachmann J, Emmerich NP, Bachor OA, and Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999 Nov; 50(3-4): 213-9.
Falk K, Rotzschke O, Stevanovic S, Jung G, and Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature. 1991 May 23;351(6324):290-6.
Deres K, Schild H, Wiesmuller KH, Jung G, and Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989 Nov; 342(6249): 561-4.

Patents

More than 140 registered or pending patents
Peptides: WO002006037421A3: Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes. WO002003100432A2: Method for identifying immunoreactive peptides WO002004085461A3: Tumour-associated peptides binding to MHC molecules
Development of mRNA vaccines: WO002003059381A2: Immunogenic preparations and vaccines on the basis of RNA. EP000001818409A1:Transfer of mRNA using polycationic compound

CV

Univ. Prof. Dr. rer. nat. Hans-Georg Rammensee